Rabbit Polyclonal TMEPAI antibody. Suitable for IHC-P, ELISA, WB, ICC/IF and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human PMEPA1.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 49% PBS, 0.88% Sodium chloride
IHC-P | ELISA | WB | ICC/IF | |
---|---|---|---|---|
Human | Tested | Expected | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 10 µg/mL | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500.00000 - 1/1000.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100.00000 - 1/500.00000 | Notes - |
Functions as a negative regulator of TGF-beta signaling and thereby probably plays a role in cell proliferation, differentiation, apoptosis, motility, extracellular matrix production and immunosuppression. In the canonical TGF-beta pathway, ZFYVE9/SARA recruits the intracellular signal transducer and transcriptional modulators SMAD2 and SMAD3 to the TGF-beta receptor. Phosphorylated by the receptor, SMAD2 and SMAD3 then form a heteromeric complex with SMAD4 that translocates to the nucleus to regulate transcription. Through interaction with SMAD2 and SMAD3, LDLRAD4 may compete with ZFYVE9 and SMAD4 and prevent propagation of the intracellular signal (PubMed:20129061, PubMed:24627487). Also involved in down-regulation of the androgen receptor (AR), enhancing ubiquitination and proteasome-mediated degradation of AR, probably by recruiting NEDD4 (PubMed:18703514).
STAG1, TMEPAI, PMEPA1, Protein TMEPAI, Prostate transmembrane protein androgen induced 1, Solid tumor-associated 1 protein, Transmembrane prostate androgen-induced protein
Rabbit Polyclonal TMEPAI antibody. Suitable for IHC-P, ELISA, WB, ICC/IF and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human PMEPA1.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 49% PBS, 0.88% Sodium chloride
TMEPAI also known as TMPRSS6-associated product containing transcript is a transmembrane protein. It has a molecular weight of approximately 26 kDa. TMEPAI is widely expressed in various tissues with particularly high expression in the lungs prostate and breast. It interacts with the cytoplasmic signaling proteins through its PY motifs modulating their activities directly. TMEPAI plays an important role in cellular pathways affecting cellular functions and interactions.
This protein modulates signaling pathways and cell growth regulation. It is well known for its involvement in the TGF-beta (Transforming Growth Factor-beta) signaling pathway. TMEPAI acts as a negative regulator inhibiting TGF-beta's tumor-suppressive functions through interaction with Smad proteins. While it does not form part of a complex itself it significantly influences the functional dynamics of the TGF-beta pathway constituents impacting cellular proliferation and survival.
TMEPAI exerts its functional significance primarily within the TGF-beta and PI3K/Akt signaling pathways. In the TGF-beta pathway TMEPAI modulates the signaling cascade by interacting with Smad2/3 and Smad4. The regulation of these proteins by TMEPAI suppresses TGF-beta-induced growth inhibition. In the PI3K/Akt pathway TMEPAI influences cell survival and proliferation indirectly through these interactions positioning it as an important modulator in these pathways.
TMEPAI has significant implications in cancer particularly in breast and prostate cancer. It facilitates cancer progression by overriding the tumor-suppressive effects of TGF-beta signaling. The interactions with Smad proteins like Smad2/3 highlight its role in oncogenic pathways. Moreover in prostate cancer the dysregulation of TMEPAI links with increased aggressive behavior of cancer cells exacerbating disease progression. Understanding these interactions provides insights into potential targets for therapeutic intervention in these diseases.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-TMEPAI antibody (ab128006) at 1/100 dilution
Lane 1: HT29 cell extract
Lane 2: HT29 cell extract with synthesized peptide
Predicted band size: 32 kDa
ab128006, at a concentration of 10 µg/ml, staining TMEPAI in paraffin-embedded Human Prostate, Smooth Muscle tissue by Immunohistochemistry.
ab128006, at a dilution of 1/100, staining TMEPAI in HuvEc cells by Immunofluorescence. The picture on the right is treated with the synthesized peptide.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com